-
公开(公告)号:US07419955B2
公开(公告)日:2008-09-02
申请号:US10514715
申请日:2003-05-26
申请人: Takashi Kadowaki , Toshimasa Yamauchi , Naoto Kubota , Yasuo Terauchi , Tetsuya Kubota , Tetsuo Noda , Ryozo Nagai , Yasushi Imai
发明人: Takashi Kadowaki , Toshimasa Yamauchi , Naoto Kubota , Yasuo Terauchi , Tetsuya Kubota , Tetsuo Noda , Ryozo Nagai , Yasushi Imai
IPC分类号: A61K38/00
CPC分类号: A61K38/2264 , A61K48/00
摘要: A scavenger receptor A expression down-regulator and a drug for preventing or treating arteriosclerosis which contain, as the active ingredient, a C-terminal globular domain of adiponectin, adiponectin, or a gene encoding the domain or adiponectin. According to the present invention, there is provided a preventive or therapeutic agent capable of directly preventing intimal thickening, which constitutes an essential feature of arteriosclerosis. This effect can be attained through arresting the onset and development of arteriosclerosis by reducing the expression level of scavenger receptor A in arterial walls and preventing lipid buildup in macrophages.
摘要翻译: 清道夫受体A表达下调和用于预防或治疗动脉硬化的药物,其含有脂联素,脂联素或编码结构域或脂联素的基因的C-末端球状结构域作为活性成分。 根据本发明,提供能够直接防止内膜增厚的预防或治疗剂,其构成动脉硬化的基本特征。 通过降低动脉壁中清道夫受体A的表达水平并防止巨噬细胞中的脂质积聚,可以通过阻止动脉硬化的发生和发展来实现该效果。
-
公开(公告)号:US20060166873A1
公开(公告)日:2006-07-27
申请号:US10514715
申请日:2003-05-26
申请人: Takashi Kadowaki , Toshimasa Yamauchi , Naoto Kubota , Yasuo Terauchi , Tetsuya Kubota , Tetsuo Noda , Ryozo Nagai , Yasushi Imai
发明人: Takashi Kadowaki , Toshimasa Yamauchi , Naoto Kubota , Yasuo Terauchi , Tetsuya Kubota , Tetsuo Noda , Ryozo Nagai , Yasushi Imai
CPC分类号: A61K38/2264 , A61K48/00
摘要: A scavenger receptor A expression down-regulator and a drug for preventing or treating arteriosclerosis which contain, as the active ingredient, a C-terminal globular domain of adiponectin, adiponectin, or a gene encoding the domain or adiponectin. According to the present invention, there is provided a preventive or therapeutic agent capable of directly preventing intimal thickening, which constitutes an essential feature of arteriosclerosis. This effect can be attained through arresting the onset and development of arteriosclerosis by reducing the expression level of scavenger receptor A in arterial walls and preventing lipid buildup in macrophages.
摘要翻译: 清道夫受体A表达下调和用于预防或治疗动脉硬化的药物,其含有脂联素,脂联素或编码结构域或脂联素的基因的C-末端球状结构域作为活性成分。 根据本发明,提供能够直接防止内膜增厚的预防或治疗剂,其构成动脉硬化的基本特征。 通过降低动脉壁中清道夫受体A的表达水平并防止巨噬细胞中的脂质积聚,可以通过阻止动脉硬化的发生和发展来实现该效果。
-
公开(公告)号:US20060059578A1
公开(公告)日:2006-03-16
申请号:US10514716
申请日:2003-05-26
IPC分类号: A01K67/027
CPC分类号: C12N15/8509 , A01K67/0276 , A01K2217/075 , A01K2227/105 , A01K2267/03 , A01K2267/0306 , A01K2267/0362 , A01K2267/0375 , C07K14/575
摘要: The animals of the present invention enable elucidation of the onset mechanisms of obesity, diabetes, and arteriosclerosis. Moreover, they are useful for screening preventive and therapeutic drugs for treating any of these diseases.
摘要翻译: 本发明的动物能够阐明肥胖,糖尿病和动脉硬化的发病机制。 此外,它们可用于筛选用于治疗任何这些疾病的预防和治疗药物。
-
公开(公告)号:US20100062541A1
公开(公告)日:2010-03-11
申请号:US12322111
申请日:2009-01-29
申请人: Takashi Kadowaki , Toshimasa Yamauchi , Ryozo Nagai , Junji Kamon
发明人: Takashi Kadowaki , Toshimasa Yamauchi , Ryozo Nagai , Junji Kamon
IPC分类号: C07K14/435 , G01N33/566
CPC分类号: C07K14/72 , Y10S435/81
摘要: The object is to isolate and identify human and mouse adiponectin receptors, to provide a novel protein having adiponectin binding ability, and to provide a screening method and screening kit for a ligand, agonist and antagonist to an adiponectin receptor using such protein. To achieve this object, a protein is used, as novel protein having adiponectin binding ability, that is (a) a protein comprising an amino acid sequence according to Seq. No. 2, 4, 6 or 8, or (b) a protein comprising an amino acid sequence according to Seq. No. 2, 4, 6 or 8 with one or more amino acids deleted, replaced or added, and having adiponectin binding ability.
摘要翻译: 目的是分离和鉴定人和小鼠脂联素受体,以提供具有脂联素结合能力的新型蛋白质,并提供使用这种蛋白质的脂联素受体的配体,激动剂和拮抗剂的筛选方法和筛选试剂盒。 为了实现这个目的,使用蛋白质作为具有脂联素结合能力的新型蛋白质,即(a)包含根据Seq的氨基酸序列的蛋白质。 No.2,4,6或8,或(b)包含根据Seq的氨基酸序列的蛋白质。 具有一个或多个缺失,替换或添加的氨基酸并具有脂联素结合能力的2,4,6或8号。
-
公开(公告)号:US07501490B2
公开(公告)日:2009-03-10
申请号:US11598474
申请日:2006-11-13
申请人: Takashi Kadowaki , Toshimasa Yamauchi , Ryozo Nagai , Junji Kamon
发明人: Takashi Kadowaki , Toshimasa Yamauchi , Ryozo Nagai , Junji Kamon
IPC分类号: C07K1/00 , G01N33/53 , G01N33/566
CPC分类号: C07K14/72 , Y10S435/81
摘要: The object is to isolate and identify human and mouse adiponectin receptors, to provide a novel protein having adiponectin binding ability, and to provide a screening method and screening kit for a ligand, agonist and antagonist to an adiponectin receptor using such protein. To achieve this object, a protein is used, as novel protein having adiponectin binding ability, that is (a) a protein comprising an amino acid sequence according to Seq. No. 2, 4, 6 or 8, or (b) a protein comprising an amino acid sequence according to Seq. No. 2, 4, 6 or 8 with one or more amino acids deleted, replaced or added, and having adiponectin binding ability.
摘要翻译: 目的是分离和鉴定人和小鼠脂联素受体,以提供具有脂联素结合能力的新型蛋白质,并提供使用这种蛋白质的脂联素受体的配体,激动剂和拮抗剂的筛选方法和筛选试剂盒。 为了实现这个目的,使用蛋白质作为具有脂联素结合能力的新型蛋白质,即(a)包含根据Seq的氨基酸序列的蛋白质。 No.2,4,6或8,或(b)包含根据Seq的氨基酸序列的蛋白质。 具有一个或多个缺失,替换或添加的氨基酸并具有脂联素结合能力的2,4,6或8号。
-
公开(公告)号:US20060199761A1
公开(公告)日:2006-09-07
申请号:US10502051
申请日:2002-07-26
申请人: Takashi Kadowaki , Toshimasa Yamauchi , Junji Kamon , Hironori Waki , Ryozo Nagai , Satoshi Kimura , Motto Tomita
发明人: Takashi Kadowaki , Toshimasa Yamauchi , Junji Kamon , Hironori Waki , Ryozo Nagai , Satoshi Kimura , Motto Tomita
CPC分类号: A61K38/2264
摘要: The invention provides an insulin resistance improving agent which contains, as an active component, a C-terminal globular domain of adiponectin, adiponectin, or a gene for the domain or adiponectin. The invention also provides a therapeutic agent for type 2 diabetes, which contains, as an active component, a C-terminal globular domain of adiponectin, adiponectin, or a gene for the domain or adiponectin. The invention reverses insulin resistance induced from a high fat diet and associated with obesity, and therefore, enables treatment of type 2 diabetes, which is the most common among other types of diabetes.
摘要翻译: 本发明提供一种胰岛素抵抗性改善剂,其包含作为活性成分的脂联素的C末端球状结构域,脂联素或所述结构域或脂联素的基因。 本发明还提供了用于2型糖尿病的治疗剂,其包含作为活性成分的脂联素的C末端球状结构域,脂联素或所述结构域或脂联素的基因。 本发明逆转高脂肪饮食诱发的胰岛素抵抗并与肥胖相关,因此能够治疗其它类型糖尿病中最常见的2型糖尿病。
-
公开(公告)号:US08252584B2
公开(公告)日:2012-08-28
申请号:US13153017
申请日:2011-06-03
申请人: Takashi Kadowaki , Toshimasa Yamauchi , Ryozo Nagai , Junji Kamon
发明人: Takashi Kadowaki , Toshimasa Yamauchi , Ryozo Nagai , Junji Kamon
CPC分类号: C07K14/72 , Y10S435/81
摘要: The object is to isolate and identify human and mouse adiponectin receptors, to provide a novel protein having adiponectin binding ability, and to provide a screening method and screening kit for a ligand, agonist and antagonist to an adiponectin receptor using such protein. To achieve this object, a protein is used, as novel protein having adiponectin binding ability, that is (a) a protein comprising an amino acid sequence according to Seq. No. 2, 4, 6 or 8, or (b) a protein comprising an amino acid sequence according to Seq. No. 2, 4, 6 or 8 with one or more amino acids deleted, replaced or added, and having adiponectin binding ability.
摘要翻译: 目的是分离和鉴定人和小鼠脂联素受体,以提供具有脂联素结合能力的新型蛋白质,并提供使用这种蛋白质的脂联素受体的配体,激动剂和拮抗剂的筛选方法和筛选试剂盒。 为了实现这个目的,使用蛋白质作为具有脂联素结合能力的新型蛋白质,即(a)包含根据Seq的氨基酸序列的蛋白质。 No.2,4,6或8,或(b)包含根据Seq的氨基酸序列的蛋白质。 具有一个或多个缺失,替换或添加的氨基酸并具有脂联素结合能力的2,4,6或8号。
-
公开(公告)号:US07977459B2
公开(公告)日:2011-07-12
申请号:US12322111
申请日:2009-01-29
申请人: Takashi Kadowaki , Toshimasa Yamauchi , Ryozo Nagai , Junji Kamon
发明人: Takashi Kadowaki , Toshimasa Yamauchi , Ryozo Nagai , Junji Kamon
IPC分类号: C07K1/00 , G01N33/53 , G01N33/566
CPC分类号: C07K14/72 , Y10S435/81
摘要: The object is to isolate and identify human and mouse adiponectin receptors, to provide a novel protein having adiponectin binding ability, and to provide a screening method and screening kit for a ligand, agonist and antagonist to an adiponectin receptor using such protein. To achieve this object, a protein is used, as novel protein having adiponectin binding ability, that is (a) a protein comprising an amino acid sequence according to Seq. No. 2, 4, 6 or 8, or (b) a protein comprising an amino acid sequence according to Seq. No. 2, 4, 6 or 8 with one or more amino acids deleted, replaced or added, and having adiponectin binding ability.
摘要翻译: 目的是分离和鉴定人和小鼠脂联素受体,以提供具有脂联素结合能力的新型蛋白质,并提供使用这种蛋白质的脂联素受体的配体,激动剂和拮抗剂的筛选方法和筛选试剂盒。 为了实现这个目的,使用蛋白质作为具有脂联素结合能力的新型蛋白质,即(a)包含根据Seq的氨基酸序列的蛋白质。 No.2,4,6或8,或(b)包含根据Seq的氨基酸序列的蛋白质。 具有一个或多个缺失,替换或添加的氨基酸并具有脂联素结合能力的2,4,6或8号。
-
公开(公告)号:US20070054314A1
公开(公告)日:2007-03-08
申请号:US11598474
申请日:2006-11-13
申请人: Takashi Kadowaki , Toshimasa Yamauchi , Ryozo Nagai , Junji Kamon
发明人: Takashi Kadowaki , Toshimasa Yamauchi , Ryozo Nagai , Junji Kamon
IPC分类号: C12Q1/68 , G01N33/567 , C07H21/04 , C12P21/06 , C07K14/705 , C07K16/28
CPC分类号: C07K14/72 , Y10S435/81
摘要: The object is to isolate and identify human and mouse adiponectin receptors, to provide a novel protein having adiponectin binding ability, and to provide a screening method and screening kit for a ligand, agonist and antagonist to an adiponectin receptor using such protein. To achieve this object, a protein is used, as novel protein having adiponectin binding ability, that is (a) a protein comprising an amino acid sequence according to Seq. No. 2, 4, 6 or 8, or (b) a protein comprising an amino acid sequence according to Seq. No. 2, 4, 6 or 8 with one or more amino acids deleted, replaced or added, and having adiponectin binding ability.
摘要翻译: 目的是分离和鉴定人和小鼠脂联素受体,以提供具有脂联素结合能力的新型蛋白质,并提供使用这种蛋白质的脂联素受体的配体,激动剂和拮抗剂的筛选方法和筛选试剂盒。 为了实现这个目的,使用蛋白质作为具有脂联素结合能力的新型蛋白质,即(a)包含根据Seq的氨基酸序列的蛋白质。 No.2,4,6或8,或(b)包含根据Seq的氨基酸序列的蛋白质。 具有一个或多个缺失,替换或添加的氨基酸并具有脂联素结合能力的2,4,6或8号。
-
公开(公告)号:US07850976B2
公开(公告)日:2010-12-14
申请号:US12041279
申请日:2008-03-03
申请人: Takashi Kadowaki , Toshimasa Yamauchi , Junji Kamon , Hironori Waki , Ryozo Nagai , Satoshi Kimura , Motoo Tomita
发明人: Takashi Kadowaki , Toshimasa Yamauchi , Junji Kamon , Hironori Waki , Ryozo Nagai , Satoshi Kimura , Motoo Tomita
CPC分类号: A61K38/2264
摘要: The invention provides an insulin resistance improving agent and a therapeutic agent for type 2 diabetes, which contain a C-terminal globular domain of adiponectin, adiponectin, or a gene for the domain or adiponectin. The invention also provides a method for improving insulin resistance and treating type 2 diabetes by administering the aforementioned agent(s).
摘要翻译: 本发明提供胰岛素抵抗改善剂和2型糖尿病治疗剂,其含有脂联素的C末端球状结构域,脂联素或结合域或脂联素的基因。 本发明还提供了一种通过施用上述药物来改善胰岛素抵抗和治疗2型糖尿病的方法。
-
-
-
-
-
-
-
-
-